US equities |
MU $937.11 ▼-1.69% NVDA $224.03 ▼-1.96% SPCX $154.62 ▼-1.22% AAPL $344.61 ▲+0.98% TSLA $368.56 ▼-1.78% META $745.86 ▼-2.18% SNDK $1,432.92 ▼-3.33% AMD $583.42 ▼-3.65%
FinancialContent

Alector, Inc. - Common Stock (NQ:ALEC)

1.875 +0.005 (+0.27%)
Delayed Quote Updated: 10:57 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alector, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in the Bank of America CNS Therapeutics Conference
From Alector, Inc.
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
--Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates-- 
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
From Alector, Inc.
Via GlobeNewswire
News headline image
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >